Florida Cancer Specialists
- Company typePrivate
- Founded1984
- HeadquartersFt Myer, United States
- Headcount1,001–5,000
- GTM typeB2C
- OfferingServices
What Florida Cancer Specialists does
Florida Cancer Specialists & Research Institute (FCS) is a private, physician-owned community oncology practice headquartered in Fort Myers, Florida, founded in 1984. It operates one of the largest community-based hematology and oncology footprints in the United States, with more than 250 physicians across nearly 100 clinic locations statewide and an employee base of 1,001-5,000. Its core product is comprehensive cancer care across all major disease sites — chemotherapy, immunotherapy, targeted therapy, bispecific antibody therapy, radiopharmaceutical therapy, radiation, CAR T-cell therapy, and supportive services — augmented by an in-house specialty pharmacy (Rx To Go, ACHC-, URAC-, and NABP-accredited), in-house genomic and germline testing, on-site pathology, PET/CT imaging, behavioral health, telehealth, and value-based-care programs.
FCS monetizes cancer care through standard payer billing (Medicare, Medicaid, and commercial insurance) for patient services, sponsored clinical trial participation (with biopharma partners including AstraZeneca, Daiichi Sankyo, and Johnson & Johnson via Sarah Cannon Research Institute), pharmacy dispensing through Rx To Go, and value-based contracts led by SVP Kiana Mehring. Its research engine is anchored by three Drug Development Units for early-phase trials (Sarasota, Lake Mary, plus a third site) and Disease Site Committees for late-phase work; the practice sustains 180+ active clinical trials and 600+ annual enrollments across 29 trial-active clinics, more than any other private oncology practice in Florida. Key strategic partners include Sarah Cannon Research Institute (research), McKesson/Ontada (real-world data), Orlando Health (co-located cancer center), the U.S. Department of Veterans Affairs (TeleOncology), and the Florida Cancer Innovation Fund.Leadership comprises CEO Ryan Ciarrocchi (with Nathan H. Walcker also referenced), CFO Charles Webb, President and Managing Physician Dr. Lucio N. Gordan, VP of Informatics Trevor Heritage, plus medical directors for drug development (Dr. Manish Patel), late-phase research (Dr. Bradley Monk), cell therapy (Dr. Shachar Peles), and research/clinical trials (Dr. Gustavo A. Fonseca). FCS is regulated through multiple national accreditations, including ACHC accreditation with distinction in oncology, and earned the ASCO Clinical Trials Participation Award. The company is not PE-backed, has no public listing, and reports revenue only through private channels; expansion is organic, driven by clinic densification in Florida, partnership-driven trial access, and adjacent research and pharmacy integration.
Florida Cancer Specialists firmographics
Firmographics- Name
- Florida Cancer Specialists
- Legal name
- Florida Cancer Specialists & Research Institute
- Website
- https://flcancer.com
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Florida Cancer Specialists industry classification
Industry- Product category
- Community Oncology and Hematology Care Services
- NAICS
- Offices of Physicians (62111), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industries
- Oncology & Cancer Specialty Hospitals (HLAFAHAC), Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Florida Cancer Specialists is headquartered
LocationHeadquarters
- HQ city
- Ft Myer
- HQ country
- United States
- HQ region
- North America
Offices16 records
Markets served
Florida Cancer Specialists business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain, Others
Revenue model
- Patient Care Services: FCS generates revenue through billable oncology and hematology care services including chemotherapy, immunotherapy, targeted therapies, radiation treatment, diagnostic imaging, laboratory services, and clinical consultations billed to Medicare, Medicaid, and commercial payers.
- Clinical Trial Participation: Revenue from conducting clinical trials in partnership with pharmaceutical companies and research organizations such as Sarah Cannon Research Institute, with trials sponsored by pharmaceutical companies including AstraZeneca, Daiichi Sankyo, and Johnson & Johnson.
- In-House Specialty Pharmacy (Rx To Go): FCS operates Rx To Go, an in-house specialty pharmacy delivering oral oncolytic therapies, generating pharmacy dispensing revenue and enabling integrated patient care.
- Value-Based Care Contracts: FCS participates in value-based oncology care arrangements with payers, including AI-powered contracting strategies and population health management programs led by SVP Kiana Mehring.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Standard oncology care services billed to Medicare, Medicaid, and commercial insurance plans. |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels8 records
Florida Cancer Specialists product offering
Product offeringCore offering
Florida Cancer Specialists & Research Institute is a community-based hematology and oncology practice delivering comprehensive cancer treatment — including chemotherapy, immunotherapy, targeted therapy, bispecific therapy, radiopharmaceutical therapy, and CAR T-cell therapy — through nearly 100 clinic locations across Florida. The practice augments direct care with an integrated specialty pharmacy (Rx To Go), genomic and germline testing, on-site pathology and PET/CT imaging, telehealth services, behavioral health support, and access to more than 180 active oncology clinical trials via three Drug Development Units.
Product overview
Florida Cancer Specialists & Research Institute operates as a statewide community oncology practice offering a comprehensive cancer care ecosystem. The core offering is cancer treatment services (chemotherapy, immunotherapy, targeted therapies, radiation, bispecific therapy) delivered through 29 clinic locations across Florida. The practice augments treatment with an integrated portfolio: an in-house specialty pharmacy (Rx To Go), genetic/genomic testing, pathology, radiology imaging, telehealth services, and behavioral health support. A distinguishing feature is its clinical trials program providing access to over 180 active trials through three drug development units, enabling patients to access emerging treatments. Support services include nutrition counseling, financial navigation, support groups, and foundation grants. The organization also participates in value-based care arrangements with payers.
Differentiator
Problem solved
Functional benefit
Brands
- Rx To Go: In-house specialty pharmacy delivering oral oncolytic therapies and personalized pharmacy services to patients across Florida
- Carespace
- Ontada Health
Products and services
- Cancer Treatment Services Comprehensive hematology and oncology care including chemotherapy, immunotherapy, targeted therapies, bispecific therapy, radiopharmaceutical therapy, CAR T-cell therapy, and radiation treatment delivered across nearly 100 Florida clinic locations for adult patients with solid tumors and blood cancers.
- Clinical Trials Program Access to more than 180 active oncology and hematology clinical trials at 29 Florida clinic locations, including three Drug Development Units (DDUs) for early-phase research conducted in partnership with Sarah Cannon Research Institute, enabling patient enrollment in cutting-edge therapies before broader commercial availability.
- Rx To Go Oral Oncolytic Pharmacy In-house specialty pharmacy delivering oral oncolytic therapies and personalized pharmacy services directly to FCS patients across Florida, achieving 95% patient satisfaction and 97-98% medication adherence rates, and accredited by ACHC with distinction in oncology, URAC, and NABP.
- Telehealth Services Virtual oncology and behavioral health consultations enabling remote access to FCS cancer specialists for patients across Florida, including telehealth therapy through seven Licensed Clinical Social Workers and participation in the VA National TeleOncology Program for veterans.
- Genomic and Genetic Cancer Testing In-house germline genetic and somatic tumor genomic profiling to identify inherited cancer risks and guide personalized cancer treatment decisions through molecular profiling.
- Radiology (PET/CT) Imaging On-site diagnostic PET/CT imaging for cancer detection, staging, and treatment response monitoring at multiple FCS clinic locations across Florida.
- Pathology Services On-site pathology and hematopathology laboratory services providing cancer diagnosis, biomarker analysis, and treatment monitoring across the practice's clinic locations.
- Behavioral Health Services Behavioral health therapy, support groups, grief counseling, and mental health services delivered by seven Licensed Clinical Social Workers to cancer patients and caregivers, including telehealth and virtual Real Talk and Caregiver Support Groups.
- DigniCap Scalp Cooling FDA-cleared scalp cooling system administered during chemotherapy to reduce chemotherapy-induced hair loss for cancer patients at FCS infusion centers.
- Value-Based Oncology Care Programs Value-based oncology care contracts and population health management programs with payers, designed to improve patient outcomes and cost efficiency across community oncology care delivery.
Quantifiable outcome
- Over 600 patient enrollments in clinical trials annually
- +8 more outcomes
Companies that use Florida Cancer Specialists
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles2 records
Florida Cancer Specialists technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Florida Cancer Specialists partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core.
- Paradigm HealthcoreParadigm Health uses its SPIRE platform as technology-enabled trial infrastructure for a multicenter, hybrid, observational post-marketing study evaluating trastuzumab deruxtecan (T-DXd) in patients with HER2 IHC 3+ solid tumors. An FCS principal investigator presented the trial design at the 2026 ASCO Annual Meeting, tracking approximately 100 patients at up to 30 U.S. locations. The trial is sponsored by AstraZeneca with co-development by Daiichi Sankyo, and is part of Paradigm Health's broader FDA collaboration on real-time clinical trials.
- U.S. Department of Veterans AffairscoreFCS collaborates with the U.S. Department of Veterans Affairs to expand veteran access to advanced cancer care, offering rapid appointments within 72 hours, telehealth via the VA National TeleOncology Program, personalized treatment using molecular profiling, and a portfolio of over 180 clinical trials at 29 clinics statewide. FCS President Dr. Lucio Gordan presented these efforts at ASCO 2026, addressing veterans' 20-40% higher cancer risk.
- McKesson / OntadacoreMcKesson's oncology insights business Ontada entered a data partnership with FCS to integrate the institute's cancer patient data into Ontada's real-world oncology dataset. The expanded dataset is designed to support biopharma partners, research stakeholders, and community oncology providers, reflecting McKesson's strategy to build data-driven services alongside its core distribution business.
- Community Oncology Alliance (COA)coreFCS senior leaders present at the COA 2026 Community Oncology Conference, leading sessions on cell therapy expansion, clinical trial access, AI tools, and quality metrics in oncology. FCS has over 40 years of experience and more than 180 active clinical trials.
- Research to PracticecoreFCS partnered with Research to Practice for the Fifth Annual National General Medical Oncology Summit in Orlando, Florida. The event convenes leading oncology experts to share cutting-edge data and emerging treatment strategies for personalized cancer care in community settings. FCS President Dr. Lucio N. Gordan emphasized that the program delivers actionable insights for medical oncologists and frontline cancer care professionals.
- AstraZeneca / Daiichi SankyocoreFCS participated in the PRESERVE-003 Phase 3 clinical trial evaluating gotistobart (CTLA-4 checkpoint-targeting immunotherapy) for metastatic non-small cell lung cancer. Results published in Nature Medicine showed improved effectiveness with fewer side effects compared to docetaxel. The trial advanced to a pivotal later stage.
- AstraZeneca / Daiichi Sankyo (Phase 1 KRAS G12D study)coreFCS participated in a Phase 1 clinical study for setidegrasib, a first-in-class KRAS G12D-targeted therapy, published in the New England Journal of Medicine. Results showed antitumor activity in lung and pancreatic cancers with low incidence of treatment discontinuation due to adverse events.
- Orlando HealthcoreFCS partnered with Orlando Health, which acquired Bayfront Health St. Petersburg, to staff a new cancer center at Orlando Health Institute Square. The partnership enables patients to access radiation oncology, medical oncology, surgical subspecialists, and clinical trials in a single location. The approximately 31,000-square-foot facility features 18 private exam rooms, 47 infusion chairs, on-site laboratory, and PET/CT imaging.
- Johnson & JohnsoncoreFCS is among the first in Florida to enroll patients in a Phase 3 clinical trial for pasritamig, a next-generation bispecific T-cell engager developed by Johnson & Johnson targeting castration-resistant prostate cancer. The trial involves 172 global locations evaluating survival benefits.
- Sarah Cannon Research InstitutecoreFCS partners with Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials. Over 110 new early-phase and 40 late-phase studies are launched annually through this partnership. FCS Director of Drug Development Dr. Manish Patel oversees early-phase research at three Drug Development Units in partnership with SCRI.
Scale indicators12 records
Recent moves8 records
Expansion highlights6 records
Florida Cancer Specialists competitors and assessment
Company assessmentDirect peers
- The US Oncology Network: The largest national network of community-based oncology practices, supported by McKesson distribution. Directly comparable to FCS in the community oncology model, with a multi-state footprint, in-house research, and specialty pharmacy capabilities.
- OneOncology: A PE-backed national platform of community oncology practices offering clinical trials, value-based care contracting, and ancillary services. Competes head-to-head with FCS for payer contracts, physician recruiting, and biopharma trial placement.
- Tennessee Oncology: Large physician-owned community oncology practice affiliated with OneOncology, operating across Tennessee and neighboring states with a comparable mix of clinical care, clinical research, and specialty pharmacy services.
- Texas Oncology: One of the largest community-based oncology practices in the US, part of the US Oncology Network. Comparable to FCS in scale, multi-site delivery, and integration of clinical trials, imaging, and pharmacy services.
- Astera Cancer Care: A multi-state community oncology practice in the Mid-Atlantic offering medical oncology, hematology, radiation oncology, and clinical trials—comparable to FCS's integrated community-based cancer care model.
- Regional Cancer Care Associates: Physician-owned community oncology practice with locations across the Northeast US. Directly comparable to FCS in the community oncology delivery model and clinical trial access.
- New York Cancer & Blood Specialists: A multi-site community oncology and hematology practice across New York state offering chemotherapy, clinical trials, imaging, and specialty pharmacy—comparable to FCS's full-stack community oncology model.
Broad incumbents
- Mayo Clinic: Major academic medical center with significant oncology presence including the Mayo Clinic Cancer Center. Competes for complex oncology cases and clinical trial referrals in Florida through the Mayo Clinic in Jacksonville.
- City of Hope: National cancer research and treatment system (including the former Cancer Treatment Centers of America) with significant Florida presence. Competes with FCS for high-acuity oncology patients and biopharma research partnerships.
Emerging players
- Sarah Cannon Research Institute: A leading community-based clinical trial management organization and FCS's primary research partner. Highly relevant as a peer for FCS's drug development operations, though SCRI is also a customer/partner rather than a direct competitor in patient-facing care.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Florida Cancer Specialists social profiles
Digital presenceFlorida Cancer Specialists compliance and trust
Trust signalCompliance5 records
Florida Cancer Specialists financial estimates
Financial estimateRevenue estimate
Valuation estimate
Florida Cancer Specialists leadership team
Management profileNumber of profiles
Profiles11 records
Florida Cancer Specialists subsidiaries and ownership
Company hierarchySubsidiaries3 records
Florida Cancer Specialists funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Florida Cancer Specialists M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Florida Cancer Specialists
What does Florida Cancer Specialists do?
Florida Cancer Specialists & Research Institute is a community-based hematology and oncology practice delivering comprehensive cancer treatment — including chemotherapy, immunotherapy, targeted therapy, bispecific therapy, radiopharmaceutical therapy, and CAR T-cell therapy — through nearly 100 clinic locations across Florida. The practice augments direct care with an integrated specialty pharmacy (Rx To Go), genomic and germline testing, on-site pathology and PET/CT imaging, telehealth services, behavioral health support, and access to more than 180 active oncology clinical trials via three Drug Development Units.
Is Florida Cancer Specialists a public or private company?
Florida Cancer Specialists is a private company. It is classified as management employee owned and is currently operating.
When was Florida Cancer Specialists founded?
Florida Cancer Specialists was founded in 1984. It employs 1,001 to 5,000 people.
Where is Florida Cancer Specialists based?
Florida Cancer Specialists is headquartered in Ft Myer, United States, in the North America region.
How does Florida Cancer Specialists make money?
Four revenue lines are on record. Patient Care Services are the primary driver. The others are clinical Trial Participation, in-House Specialty Pharmacy (Rx To Go) and value-Based Care Contracts.
Who are Florida Cancer Specialists's main competitors?
Direct peers on record are The US Oncology Network, OneOncology, Tennessee Oncology, Texas Oncology, Astera Cancer Care, Regional Cancer Care Associates and New York Cancer & Blood Specialists. Broad incumbents are Mayo Clinic and City of Hope. Sarah Cannon Research Institute is listed as an emerging player.
Does Florida Cancer Specialists have an API?
No public API is recorded for Florida Cancer Specialists.
What industry is Florida Cancer Specialists in?
Florida Cancer Specialists's product category is Community Oncology and Hematology Care Services. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAFAHAC, Oncology & Cancer Specialty Hospitals. Its NAICS code is 62111 and its SIC code is 8011.